Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 951 - 975 of 14593 in total
Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America.
Approved
Matched Description: … Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle …
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …
An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.
Approved
Investigational
Matched Description: … An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. …
Matched Categories: … Ergot Alkaloids and Derivatives …
Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis infections.[L44592,L44597] Sulconazole appears to be effective...
Approved
Matched Description: … Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and ... [L44592,L44597] Sulconazole appears to be effective and well-tolerated in the treatment of superficial ... inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and
Matched Categories: … Imidazole and Triazole Derivatives …
Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About...
Approved
Investigational
Matched Description: … [L8063] Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized ... [A32023] Adolescent patients with cataplexy also experienced a slight improvement in the frequency and ... treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020....
Approved
Matched Description: … stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and ... Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile, prodrug ,fenofibrate, and other conjugated compounds...
Approved
Matched Description: … for improved solubility, gastrointestinal absorption, and bioavailability, and more convenient administration ... acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and ... ], and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have been developed …
Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds...
Approved
Matched Description: … H1, muscarinic, and serotonin type 2 (5-HT2) receptors. ... Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of ... schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. …
Matched Categories: … Hypnotics and Sedatives …
Technetium Tc-99m sestamibi (commonly sestamibi) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands, hence the name sesta (6) MIBI.. Following intravenous injection of the drug, Technetium Tc-99m sestamibi is taken up by...
Approved
Investigational
Matched Description: … infarction (non-reversible defects); and 2) evaluating myocardial function and developing information ... intravenous injection of the drug, Technetium Tc-99m sestamibi is taken up by the myocardium, parathyroid, and ... indicated for: 1) detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and
Matched Categories: … Indicators and Reagents …
Polyquaternium-10 is a quaternized hydroxyethyl cellulose and a polycationic polymer. It is commonly found in cosmetics and personal care products to mainly reduce static electricity and form films.
Approved
Matched Description: … It is commonly found in cosmetics and personal care products to mainly reduce static electricity and ... Polyquaternium-10 is a quaternized hydroxyethyl cellulose and a polycationic polymer. …
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Approved
Investigational
Matched Description: … Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX. ... [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the...
Approved
Matched Description: … The difference in density between the gas-filled bubbles and the blood around them creates an increased ... When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Ethyl macadamiate is derived from Macadamia terifolia seed oil. It is a non-volatile ester of ethyl alcohol and the fatty acids. Ethyl macadamiate is used in cosmetics and personal care products such as sunscreen, hair care products and skin care products as an emollient and skin conditioning agent.
Approved
Matched Description: … and skin care products as an emollient and skin conditioning agent. ... It is a non-volatile ester of ethyl alcohol and the fatty acids. ... Ethyl macadamiate is used in cosmetics and personal care products such as sunscreen, hair care products …
Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. A common pharmaceutical formulation of thonzonium bromide is...
Approved
Matched Description: … It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular ... Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. ... debris and exudate, thereby promoting tissue contact of the administered medication. …
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha...
Approved
Investigational
Withdrawn
Matched Description: … It has been reintroduced and used for a number of inflammatory disorders and cancers. ... inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. ... Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness,...
Approved
Investigational
Vet approved
Matched Description: … for induction and/or maintenance of anaesthesia prior to and during surgeries. ... Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia ... effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. …
Matched Categories: … Hypnotics and Sedatives …
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists...
Approved
Investigational
Matched Description: … [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine ... L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and ... was subsequently approved by the European Commission in April 2022 for both the treatment and prevention …
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms...
Approved
Matched Description: … increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and
Matched Categories: … Scabicides, Insecticides and Repellents ... Antiparasitic Products, Insecticides and Repellents …
Ethylhexyl methoxycrylene is a photostabilizer that preserves the effectiveness of UV filters by interacting with both the singlet and triplet states . It returns UV filters to their ground states without absorbing sunlight . It is used as a solvent for crystalline UV filters and is easily emulsified and suitable...
Approved
Experimental
Matched Description: … It is used as a solvent for crystalline UV filters and is easily emulsified and suitable for use in various ... lotions, creams, sprays, sticks, and gel formulations [F104]. ... It currently enjoys regional approvals in Canada, the EU, and the US [L2847]. …
Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing the...
Approved
Matched Description: … selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and ... cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing the synthesis ... Compared to [sildenafil] and [tadalafil], vardenafil is a more potent inhibitor of PDE5; however, its …
Matched Categories: … Genito Urinary System and Sex Hormones …
Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia. It was first marketed in 1996 in several European countries before being withdrawn two years later because of...
Approved
Investigational
Withdrawn
Matched Description: … It has once again been approved and should soon be available on the French and Australian market. …
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive...
Approved
Investigational
Matched Description: … as amitriptyline and clomipramine. ... TCAs are potent inhibitors of serotonin and norepinephrine reuptake. ... reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. …
Matched Categories: … Tricyclics and Other Norepinephrine-reuptake Inhibitors …
Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. As well, moxonidine has been shown...
Approved
Investigational
Matched Description: … suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and
Matched Categories: … moxonidine and diuretics …
Approved
Experimental
Matched Categories: … Diet, Food, and Nutrition …
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn
Matched Categories: … Benzamides and benzamide derivatives …
Terbutaline was first synthesized in 1966 and described in the literature in the late 1960s and early 1970s. It is a selective beta-2 adrenergic agonist used as a bronchodilator in asthmatic patients.[A230333,L32093,L32098] Terbutaline was granted FDA approval on 25 March 1974.
Approved
Matched Description: … and early 1970s. ... Terbutaline was first synthesized in 1966[A230333] and described in the literature in the late 1960s …
Displaying drugs 951 - 975 of 14593 in total